Through ADA treatment, which curtails survival-promoting genes like BCL-2 and activates pro-apoptosis mediators (PARP and cleaved-Caspase 3), effective induction of apoptosis in MM cells can be achieved. The gene discussed is ADA; the disease is Miyoshi myopathy.